# Staidson (Beijing) Biopharmaceuticals trials: 28 (2026)

ClinicalTrials.gov lists 28 trials with Staidson (Beijing) Biopharmaceuticals Co., Ltd as lead sponsor, 5 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Staidson (Beijing) Biopharmaceuticals Co., Ltd: 28 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/staidson-beijing-biopharmaceuticals-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 28
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 25 newest of 28, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 22, 2026 | NCT07833943 | A Study to Evaluate the Safety and Efficacy of Multiple Dose of STSP-0902 in Patients With Oligozoospermia and/or Asthenozoospermia. | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 2 | Not yet recruiting | Oligozoospermia and/or Asthenozoospermia | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833943) |
| October 6, 2025 | NCT07208591 | To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 3 | Recruiting | Acute Respiratory Distress Syndrome (ARDS) | 406 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07208591) |
| September 11, 2025 | NCT07168161 | BDB-001 Phase III Trial in ANCA-Associated Vasculitis | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 3 | Recruiting | ANCA Associated Vasculitis (AAV) | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07168161) |
| May 16, 2025 | NCT06975748 | A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 2 | Recruiting | Neurotrophic Keratitis | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06975748) |
| April 29, 2025 | NCT06948799 | A Study to Evaluate the Safety and Tolerability of Single and Multiple Dose of STSP-0902 in Healthy Subjects | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1 | Recruiting | Oligozoospermia | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06948799) |
| September 19, 2024 | NCT06597422 | A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1 | Completed | Neurotrophic Keratitis | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06597422) |
| August 21, 2024 | NCT06563713 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STSP-0902 in Healthy Subjects | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1 | Completed | Oligozoospermia, Asthenozoospermia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06563713) |
| March 1, 2024 | NCT06289166 | Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 2 | Completed | Hemophilia | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06289166) |
| November 28, 2023 | NCT06148389 | The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1 | Completed | Primary Immune Thrombocytopenia | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06148389) |
| September 15, 2023 | NCT06038916 | To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1/2 | Completed | Acute Respiratory Distress Syndrome | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06038916) |
| August 14, 2023 | NCT05986877 | A Study of STSA-1201 in Healthy Subjects | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1 | Completed | Healthy | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05986877) |
| March 8, 2023 | NCT05760781 | To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 2 | Terminated | Chronic Hepatitis b | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05760781) |
| March 8, 2023 | NCT05760703 | Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 2 | Terminated | Chronic Hepatitis b | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05760703) |
| January 27, 2023 | NCT05702983 | The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1 | Completed | Antineutrophil Cytoplasmic Antibody Associated Vasculitis | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05702983) |
| November 17, 2022 | NCT05619926 | Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 2 | Completed | Hemophilia | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05619926) |
| September 29, 2022 | NCT05559125 | A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1 | Terminated | Healthy Subject | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05559125) |
| August 11, 2022 | NCT05497635 | A Study of STSA-1002 in Healthy Subjects | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1 | Completed | Healthy Subject | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05497635) |
| May 4, 2022 | NCT05361005 | Tolerability and Safety of BDB-001 Injection in Healthy Subjects | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1 | Completed | Healthy | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05361005) |
| May 4, 2022 | NCT05360927 | Safety and Tolerability of BDB-001 Injection in Healthy Subjects | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1 | Completed | Healthy | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05360927) |
| January 20, 2022 | NCT05197842 | Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic... | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1/2 | Completed | ANCA-associated Vasculitis | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05197842) |
| December 22, 2021 | NCT05166837 | The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1 | Completed | Healthy | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05166837) |
| November 2, 2021 | NCT05103423 | Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1/2 | Completed | Hidradenitis Suppurativa | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05103423) |
| October 26, 2021 | NCT05093855 | Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 2 | Completed | Hidradenitis Suppurativa | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05093855) |
| October 12, 2021 | NCT05075304 | A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1 | Terminated | COVID-19 | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05075304) |
| September 2, 2021 | NCT05032144 | The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1 | Completed | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05032144) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 1/2 | 4 |
| Phase 2 | 7 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 18 |
| Terminated | 5 |
| Recruiting | 4 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hemophilia A | 4 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 3 |
| Oligospermia | 2 |
| Hepatitis B, Chronic | 2 |
| Hidradenitis Suppurativa | 2 |
| COVID-19 | 2 |
| Respiratory Distress Syndrome | 2 |
| Asthenozoospermia | 1 |
| Pneumonia | 1 |
| Purpura, Thrombocytopenic, Idiopathic | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Office supply stores in the United States](https://specstream.ai/data/businesses/office-supply-stores/united-states)
- [Nephrology practices in the United States](https://specstream.ai/data/businesses/nephrology-practices/united-states)
- [Mongolian restaurants in the United States](https://specstream.ai/data/businesses/mongolian-restaurants/united-states)
- [Medical transportation companies in the United States](https://specstream.ai/data/businesses/medical-transportation-companies/united-states)
- [Meat wholesalers in the United States](https://specstream.ai/data/businesses/meat-wholesalers/united-states)
- [Lumber stores in the United States](https://specstream.ai/data/businesses/lumber-stores/united-states)
